A Multicenter Open-Label Study of RMC-6236 in Patients with Advanced Solid Tumors Harboring Specific Mutations in KRAS
Contact:
NCT Number:
Protocol:
AAAU3070
Study Status:
Active/Enrolling
Population:
Pediatrics/Adult
Phase:
I
The purpose of this study is to test an experimental drug called RMC-6236 (the study drug) for solid tumor cancer with a KRAS mutation. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals, and this blocking action may slow or stop the growth of your cancer cells. RMC-6236 is an experimental drug, which means that it is not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC-6236 will be tested in humans. The safety of different doses of RMC-6236 and how it is processed by your body will be tested.
Are you Eligible? (Inclusion Criteria)
- Subject must be ≥18 years of age 2. Life expectancy of >3 months 3. Subjects must be able to take PO (by mouth) medications and be willing to record daily adherence records. 4. Subjects must be able to fast for ≥12 hours.
Specialty Area(s)
Bladder Cancer , Breast Cancer, Colon and Rectal Cancer, Ovarian Cancer, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Liver Cancer, Lung cancer, Pancreatic Cancer, Prostate Cancer, Stomach Cancer, Testicular Cancer, Thyroid Cancer
Principal Investigator
Trial Location(s)
CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032
